Regeneron’s Claims Ledger: What Management Said, What the Filings Show, and What October 30 Will Settle
Regeneron spent most of 2024 and 2025 telling investors a story about transition: EYLEA, its aging...
Lowe’s Narrows the Range: What the Call Revealed That the Filing Couldn’t Hide
For most of the past decade, Lowe's has been a story of patient reinvention. The company...
Lilly’s Claims Ledger: What the Call Said, What the Filing Voted, What Held Up
In one breath Eli Lilly's Q2 2026 10-Q confirms revenue nearly doubling in two years, with...
Hill or Cliff? The One Exchange That Defines Merck Right Now
In one breath Merck's filed revenue is growing and its newest drugs are landing approvals, but...
The Margin That Vanished: Meta’s Q2 Call vs. the Filed Record
In one breath Meta's revenue is growing faster than almost anyone expected. Its profit, for this...
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the TerminalA BullScope product
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.